I/O Summit Europe 2024
Hilton London Canary Wharf S Quay Square, Marsh Wall, London, United KingdomJoin Discovery Life Sciences at I/O Summit Europe 2024 April 23-25, 2024 | Hilton London Canary Wharf, London, England
Discovery provides pharmaceutical and biotech researchers with access to diverse expertise, advanced technologies, and customizable solutions, all performed in our state-of-the-art CLIA-certified, CAP-accredited, and GCLP-compliant laboratories.
We have the world’s largest commercial biorepository and multi-omic biomarker services supported by a large network of pathologists and clinical sites.
Discovery’s biomarker services offer flexibility and the ability to generate high quality data. We deliver faster turnaround times while preserving samples by simultaneously testing samples using our integrated, multi-omic workflows.
Our experts use the latest technologies to understand biomarker assays across diverse indications quickly and help develop robust assays to identify more specific patients for clinical trials.
Reliable and customizable proteomic services – from multiplex immunoassays such as Luminex and Olink to mass spectrometry – enabling improved understanding of real-time human biology.
High-throughput RNA-Seq, WES, long-read, single cell sequencing, targeted sequencing or WES workflows optimized in GCLP-compliant service laboratory for the most challenging sample types such as FFPE and core needle biopsies.
Discovery’s clinical flow cytometry laboratory delivers high-resolution multiparametric flow cytometry data for rapid, high-throughput screening of compounds assessing their effects on cellular targets, efficacy in disease models, and identification of potential therapeutic candidates.
Pathologist-driven, GCLP-compliant procedures for developing and validating AI driven digital image analysis and custom IHC/mIF assays in CAP-accredited and CLIA-certified GCLP compliant laboratories.
Discovery conducted a retrospective, exploratory RNA sequencing study in collaboration with Karyopharm Therapeutics using FFPE dedifferentiated liposarcoma (DD-LPS) tumor samples revealing a potential predictive biomarker.Download
Discovery developed an assay with dynamic range, high precision and reproducibility, laying the foundation for the successful 22C3 PD-L1 companion diagnostic assay widely utilized today.Download
Discovery has been instrumental in helping determine HER2 assay design, evaluation, scoring, and clinical utility for use in breast, esophageal and gastric cancers.Download
Contributing to the ORIEN Avatar program, Discovery Genomics has conducted high yield, high quality dual RNA/DNA isolation from FFPE specimens, WES and RNA-Seq services on more than 30,000 tumor and non-tumor samples. Watch Webinar
Discovery has supported major government-funded projects, including NIH’s Gabriella Miller Kids First and All of Us programs. We have tested over 50,000 NGS samples for ongoing government collaborations.
With our extensive experience in aligning government priorities with cutting-edge technologies and resources, Discovery is dedicated to assisting our biopharma partners in maximizing their chances of winning government-funded projects.
Join Discovery Life Sciences at I/O Summit Europe 2024 April 23-25, 2024 | Hilton London Canary Wharf, London, England
Join Discovery Life Sciences in Booth #11 at CB & CDx London 2024 April 24-25, 2024 | Millennium Gloucester Hotel London Kensington, London, England
Join Discovery Life Sciences at Cyto Conference 2024 May 4-8, 2024 | Edinburgh International Convention Center, Edinburgh, Scotland
Copyright © 2024 Discovery Life Sciences. All rights reserved.
Designed & Developed by Altitude Marketing